ConvaTec Group (LON:CTEC) Given “Buy” Rating at Stifel Nicolaus

Stifel Nicolaus reissued their buy rating on shares of ConvaTec Group (LON:CTEC) in a research note released on Wednesday, MarketBeat.com reports. The firm currently has a GBX 315 price objective on the stock.

A number of other research analysts also recently issued reports on the stock. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of ConvaTec Group in a research report on Friday, November 14th. Peel Hunt reaffirmed an “add” rating and issued a GBX 270 price target on shares of ConvaTec Group in a research note on Thursday, November 13th. Citigroup reiterated an “outperform” rating and set a GBX 315 price objective on shares of ConvaTec Group in a report on Thursday, March 5th. Finally, Berenberg Bank raised their target price on ConvaTec Group from GBX 330 to GBX 340 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of GBX 319.

ConvaTec Group Price Performance

LON:CTEC opened at GBX 236.20 on Wednesday. The company has a market cap of £4.60 billion, a P/E ratio of 27.47, a P/E/G ratio of 0.93 and a beta of 0.76. The firm’s fifty day moving average price is GBX 235.80 and its two-hundred day moving average price is GBX 236.67. The company has a debt-to-equity ratio of 106.19, a current ratio of 1.53 and a quick ratio of 0.96. ConvaTec Group has a one year low of GBX 209.40 and a one year high of GBX 311.20.

About ConvaTec Group

ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.